What type of study is this?

This is a Human Clinical Trial study (also classified as: Pre-Registered Trial).

What question did this study set out to answer?

To assess the safety and efficacy of iadademstat combined with azacitidine and venetoclax in newly diagnosed AML.

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Preliminary results show that iadademstat with azacitidine and venetoclax is safe, with manageable adverse events in newly diagnosed AML.

To assess the safety and efficacy of iadademstat combined with azacitidine and venetoclax in newly diagnosed AML.
Phase 1b study of iadademstat (LSD1 inhibitor) in combination with azacitidine and venetoclax
Enrollment of patients with newly diagnosed AML or MDS/AML overlap
Evaluation of maximum tolerated dose and recommended phase 2 dose
Use of a Bayesian optimal interval design
0 dose-limiting toxicities observed in 6 evaluable patients
88% complete remission rate among patients
100% overall response rate with manageable adverse events
Median age of participants was 70 years, predominantly male and White

Lachowiez et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark